How does semaglutide produce its weight-management effect?
Semaglutide is a GLP-1 receptor agonist — a synthetic compound that binds to and activates GLP-1 receptors throughout the body. The GLP-1 receptor is expressed in the hypothalamus and brainstem (where hunger and satiety signals are processed), the stomach (where it slows gastric emptying), and the pancreas (where it supports insulin secretion in a glucose-dependent fashion).
Semaglutide’s half-life is approximately one week, achieved through structural modifications that protect it from enzymatic degradation. This is what makes once-weekly dosing possible and what distinguishes it pharmacologically from natural GLP-1, which degrades within minutes.
The appetite-suppressing effect at the hypothalamic level is central to weight management outcomes. Patients typically describe a reduced interest in food — less hunger, reduced cravings, and more easily recognizing satiety. This effect is dose-dependent, which is why the dose you start on is rarely the dose where you see the most meaningful response.
What is the standard semaglutide titration schedule for weight loss?
Titration schedules for semaglutide dosing for weight loss are modeled on the clinical trial escalation protocols and refined through clinical experience. The typical structure:
| Phase | Weeks | Dose (weekly) | Primary purpose |
|---|---|---|---|
| Introduction | 1–4 | 0.25 mg | Tolerability establishment |
| Step 1 | 5–8 | 0.5 mg | First therapeutic tier; appetite suppression begins |
| Step 2 | 9–12 | 1.0 mg | Sustained results; maintenance dose for many patients |
| Step 3 (if indicated) | 13–16 | 1.7 mg | Used if 1.0 mg response has plateaued |
| Maintenance max (if indicated) | 17+ | 2.4 mg | Ceiling studied in STEP 1 trial (~15% weight reduction) |
Compounded semaglutide prescribed through a licensed 503A pharmacy is patient-specific. Your clinician prescribes the exact concentration and volume for each injection — not a fixed commercial pen. No hidden overseas supply chain. Compounded in the USA by licensed 503A pharmacies.
When should you advance to the next semaglutide dose — and when should you hold?
Titration is not a rigid calendar schedule. The decision to advance to the next dose level involves two conditions:
- Tolerability at the current dose is established. GI side effects (nausea, delayed gastric emptying, occasional vomiting) should be manageable and trending toward resolution before you increase. Advancing while side effects are still significant risks compounding them.
- Response at the current dose is insufficient for the clinical goal. If you are progressing well at 1.0 mg, advancing to 1.7 mg may not be necessary. The goal is the lowest effective dose, not the maximum dose.
If side effects are significant at a given step, the standard protocol is to hold at that dose for an additional four weeks — or longer — before advancing. Your clinician makes this call based on check-in data, not a fixed calendar.
How do you find your maintenance dose?
The maintenance dose is where you want to stay long-term: the dose that produces the response you need with an acceptable side effect profile. For some patients, that is 1.0 mg. For others, it is 2.4 mg. The STEP 1 trial used a 2.4 mg ceiling, but clinical practice shows that meaningful weight management is achievable across a range of doses.
Clinicians following evidence-based protocols look for the minimum effective maintenance dose — not the maximum. Higher doses carry higher side effect burden for many patients, and adherence over a 12–18 month protocol matters more than the absolute dose level.
Once weight management goals are reached, a lower-dose maintenance protocol is an option to sustain results without continuing to drive further reduction. This is discussed with your clinician based on your individual trajectory and goals.
What affects your semaglutide dose decision?
Several clinical factors shape how your semaglutide dosing protocol is designed:
- Medical history: Prior GI conditions, history of pancreatitis, personal or family history of certain thyroid conditions, and other clinical factors influence eligibility and protocol design.
- Concurrent medications: Semaglutide slows gastric emptying, which can affect absorption timing for other oral medications. Clinicians consider this when designing protocols.
- Baseline weight and metabolic profile: Starting weight, insulin sensitivity, and metabolic labs inform expectations and help calibrate what a meaningful response looks like at each dose level.
- Prior GLP-1 exposure: Patients who have previously used semaglutide or another GLP-1 receptor agonist may not need to retitrate from zero, depending on how long ago they stopped and their prior dose level.
How are side effects managed across the dose ladder?
Nausea is the most commonly reported side effect at each dose increase. It is typically most pronounced in the first one to two weeks after each step up and tends to resolve as the body adjusts.
Strategies that help with tolerability:
- Eating smaller portions and stopping before feeling full
- Avoiding high-fat, fried, or rich foods — these amplify delayed gastric emptying
- Injecting in the evening so the acute post-dose window passes during sleep
- Staying hydrated and eating slowly
If side effects are not resolving or are severe, contact your clinician. Dose holds and temporary step-downs are both established parts of the protocol.
Frequently asked questions
What is the starting semaglutide dose for weight loss?
The standard starting dose is 0.25 mg injected subcutaneously once weekly for the first four weeks. This introductory dose is designed to establish tolerability rather than drive immediate weight reduction. The appetite-suppressing effect becomes more pronounced at higher doses reached during titration.
How long does semaglutide titration take?
Most titration protocols take 16 to 20 weeks to reach the 2.4 mg maintenance dose used in the STEP 1 trial. However, many patients reach a clinician-determined maintenance dose earlier — often at 1.0 mg or 1.7 mg — if that level is producing the desired response with acceptable tolerability.
What is the maintenance dose of semaglutide for weight loss?
The maintenance dose is the dose where you achieve your weight management goals with manageable side effects. Clinical trials studied doses up to 2.4 mg weekly, but many patients sustain results at lower doses. Your clinician calibrates the maintenance dose to your specific response — it is not automatically the maximum available.
Is compounded semaglutide the same dose as branded versions?
Compounded semaglutide is dosed in the same unit (milligrams) as its branded counterpart. However, compounded formulations from licensed 503A pharmacies are patient-specific — your clinician prescribes the exact concentration and volume for your protocol, which may be drawn from a vial rather than a fixed-dose pen.
What should I do if I have side effects at a semaglutide dose?
Contact your clinician. If GI side effects are significant, the standard approach is to hold at the current dose longer before advancing — not to push through to the next step on schedule. In some cases, stepping back to the previous dose temporarily is appropriate.
Can I stay on semaglutide after reaching my weight goal?
Yes. Maintenance protocols exist specifically for this purpose, often at a lower dose than the one used to reach the goal. Stopping semaglutide entirely is associated with weight regain for many patients, so clinicians discuss a long-term plan — often including a lower maintenance dose — before discontinuation.
Learn more about compounded semaglutide or compare with tirzepatide to understand which may be right for your situation.